Please login to the form below
drug side effects
This page shows the latest drug side effects news and features for those working in and with pharma, biotech and healthcare.
FDA approves first drug to delay onset of type 1 diabetes
The most common side effects of the drug include decreased levels of certain white blood cells, rash and headache. ... The drug’s potential to delay clinical diagnosis of type 1 diabetes may provide patients with months to years without the burdens of
Latest news
-
Novartis to temporarily suspend Huntington’s disease phase 2b study after side effects reported
Novartis will temporarily suspend dosing of branaplam (LM1070) in a phase 2b Huntington’s disease (HD) study following a data review which revealed the drug might be causing side effects on ... The treatment received fast track designation by the US
-
FDA narrows label for Biogen’s Aduhelm to only include mild forms of Alzheimer’s disease
s common and potentially serious side effects.”. ... This reflects a discount of 85-95% on the drug’s current list price.
-
FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision
If Aduhelm fails to prove its clinical benefit for patients, the FDA can choose to withdraw the approval of the drug. ... s common and potentially serious side effects,” ICER said in a statement.
-
MSD launches antibiotic combo Recarbrio in UK
The result was particularly significant, given that colistin is often reserved as a ‘last-line’ therapeutic for Gram-negative infections, although the drug can have significant side-effects including kidney damage. ... According to the World Health
-
Sobi’s Gamifant receives final rejection from CHMP for primary HLH
drug’s side effects. ... Gamifant was approved by the US Food and Drug Administration (FDA) for the treatment of primary HLH in November 2018.
More from news
Approximately 1 fully matching, plus 114 partially matching documents found.
Latest Intelligence
-
Where next in Alzheimer’s disease R&D?
Much of this research centred on improving the selectivity of compounds so that they hit the target, M1, without also interacting with similar receptors linked to the intolerable side effects. ... Meanwhile, Karuna Pharmaceuticals has raised $42m to
-
Redirecting your patient strategy
But when people are dealing with their condition for so long, it is important that you understand how they're actually managing it, how they're using the drug.”. ... These new companies have developed novel business models based on sharing the data and
-
Choices, choices: the rapidly evolving HIV treatment landscape
IIs are more potent, with fewer side effects and drug interactions and the top reason for prescribing them is their good tolerability profile. ... As patients differ so do their barriers to adherence, whether this be complexity of the dosing regimen,
-
Patients First
to their thoughts on the impact of drug side effects, these are all areas that pharma is already actively engaged with at some level.
-
Oncology drugs under AMNOG: part two
The G-BA assesses drugs on four criteria: mortality; morbidity (for example, symptom improvement); quality of life; and adverse events (toxicity and side effects). ... A natural question to ask is how the benefit finding impacts the final price of a drug
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
Practical advice for Early Scientific Advice (ESA) in HTA submissions
Payers must take into consideration not only the clinical efficacy of a drug, but also its safety profile, side effects, and cost-effectiveness, among other factors.
-
My MS journey: one patient's search for innovation
I’ve also seen a neuro-urologist who deals with bladder problems. The problem is, each specialist may give you a drug which can have unpleasant side effects, causing another layer
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- How an AI algorithm might save your life
- Navigating patients step by step on their clinical trial journey
- Innovative Trials responds to national recommendations to tackle UK clinical trial decline
- AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer
- BMS presents positive four-year results for Opdivo combination in lung cancer
- Tuberculosis – why it remains a major global public health challenge
- Whitepaper: Closing the gap with compelling healthcare communications
No results were found
PMHub
11 London
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...
Latest intelligence
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
